Skip to main content
OpenTrials
Recruiting

NCT Number: NCT01802034

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

A central goal of this data repository is to collect data from a large population of subjects with a variety of renal disease states. Cohorts will include subjects with diabetes, inflammatory/autoimmune and transplant related renal conditions. Additionally, the repository will have the capacity to store biospecimens and electronic data in control subjects without established renal disease. This initiative will provide an opportunity to compare data from various disease states and controls with the objective of determining clinical and biological factors that predict disease progression, response to therapy and identify discriminating noninvasive clinical and biological features that predict renal biopsy findings.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The Rogosin Institute

New York, 10021, United States

Location status: Recruiting

Location contact

Alan S Perlman, MD

PRINCIPAL_INVESTIGATOR

Betty-Jane Sloan, M.A.

CONTACT

[email protected]

646-317-0701

Choli Hartono, MD

SUB_INVESTIGATOR

Daniel M Levine, PhD

SUB_INVESTIGATOR

David Serur, MD

SUB_INVESTIGATOR

James M Chevalier, MD

SUB_INVESTIGATOR

John CL Wang, MD

SUB_INVESTIGATOR

Jun Lee, MD

SUB_INVESTIGATOR

Liu M Frank, MD

SUB_INVESTIGATOR

Manikkam Suthanthiran, MD

SUB_INVESTIGATOR

Meredith J Aull, PharmD

SUB_INVESTIGATOR

Nathaniel Berman, MD

SUB_INVESTIGATOR

Nelson Chen, CRC

SUB_INVESTIGATOR

Surya V Seshan, MD

SUB_INVESTIGATOR

Thomas S Parker, PhD

SUB_INVESTIGATOR

About this study

RENAL AID is designed as an inclusive data and tissue repository that is capable of linking demographic, clinical, laboratory, histology, genetic and radiographic data into one interconnected electronic data collection instrument. It is hypothesized that by linking these typically disconnected data components into a single electronic repository, RENAL AID will be capable of discovering relationships between these otherwise disparate data sets in order to ascertain previously unknown factors and associations that contribute to the progression of disease, the incidence of complications (including renal failure) and response to therapy. Further, certain patterns of inflammatory and/or immune mediators present in the serum, whole blood and urine of subjects with renal disease may be predictive of the underlying histopathology present in renal biopsy specimens. The potential correlation of non-invasive markers with underlying histopathology in subjects undergoing renal biopsy may afford the ability to make renal diagnoses non-invasively in the future.

RENAL AID will obtain and follow clinical data on large numbers of subjects from a variety of ethnic, social and economic backgrounds in the following three research subject groups:

  • Native Biopsy Tissue Group: This group consists of subjects for which an expectant renal biopsy is undertaken based upon clinical necessity for whom surplus tissue is available. Subjects enrolled in this group will be evaluated every 3 months for the first year following biopsy, then annually thereafter. Research whole blood, serum and urine will be obtained at these visits.
  • Native kidney, non-tissue group: This group consists of subjects who have undergone a renal biopsy without specimen storage in the RENAL AID biorepository and/or subjects who have diabetes and concurrent kidney disease in the absence of a renal biopsy. Subjects enrolled in this group will be evaluated annually. Research whole blood, serum and urine will be obtained at these visits.
  • Allograft tissue group: This group consists of subjects that have undergone a renal transplant and require a transplant biopsy for either surveillance (termed protocol biopsy) or "for-cause" indications. By definition, "for-cause" biopsies are performed when an unexpected clinical event occurs that warrants transplant biopsy. Such events include acute graft dysfunction, progressive decline of transplant function, proteinuria and hematuria. Subjects in this group will be evaluated at the time of the transplant biopsy and research whole blood, serum and urine will be obtained at the visit.

Additionally, as RENAL AID is designed as both a biospecimen and data repository with the objective to conduct a wide variety of diverse research based upon the data and tissue collected, there will be research investigations for which control subjects are necessary. In anticipation of this requirement, RENAL AID will have the ability to record clinical, laboratory and histology data on control subjects in the same manner as for research subjects for those studies that obligate a control group and will have the ability to store bio-specimens and tissue in the same manner as for research subjects. In these circumstances, control subjects will be consented and RENAL AID will store electronic data and biopspecimens per protocol.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

All Groups:

  • Males or females
  • 18 years of age and older
  • Willing and able to provide informed consent

Native Biopsy Tissue Group:

  • Require an initial kidney biopsy for medical necessity

Native Kidney, Non-tissue Group:

  • Previously had a kidney biopsy and the tissue is not stored in this biorepository; or
  • Have diabetes and kidney disease and have not had a kidney biopsy

Allograft Tissue Group:

  • Have undergone a renal transplant and require a transplant biopsy for either surveillance or "for-cause" indications.

Key Exclusion Criteria for all Groups:

  • Inability to provide informed consent.

Treatment and study plan

Primary outcomes

  1. Change in disease progression

    Time frame: Up to 10 years

Study contacts

Contact information is provided by the study sponsor or research team.

Alan Perlman, M.D.

CONTACT

[email protected]

212-746-1580

Nelson Chen, M.A.

CONTACT

[email protected]

646-317-0785

Sponsors and collaborators

Lead sponsor

The Rogosin Institute

Other

Collaborators

  • New York Presbyterian Hospital
  • Weill Medical College of Cornell University

Registry information

Acronym: RENAL AID

Important dates

Study start
2013
Primary completion
2028
Study completion
2028
First posted
Mar 1, 2013
Registry last updated
Apr 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.